HIV drug side effects: new study probes liver damage risk
NCT ID NCT00326482
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 3 times
Summary
This study looked at liver fibrosis (scarring) in 127 HIV patients who had high liver enzymes while on antiretroviral therapy. Participants underwent tests like liver biopsy, ultrasound, and CT scans to measure liver damage. The goal was to understand how common and severe liver fibrosis is in this group, helping guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better understand and monitor liver damage in HIV patients on antiretroviral therapy.
- What could go wrong
- This is an observational pilot study, not a treatment trial. It may not lead to direct benefits for participants, and liver biopsy carries risks like bleeding or infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ELEVATED TRANSAMINASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new strategy break the cycle of HIV care dropout?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can extra doses of an old drug reverse liver scarring?
- Can Weight-Loss surgery beat drugs for advanced liver damage?
- Smart pill bottles and health coaches team up to tackle HIV in the deep south
- Navy beans take on fatty liver: a diet swap put to the test